Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
13.12
+0.03 (0.23%)
At close: May 29, 2026, 4:00 PM EDT
13.31
+0.19 (1.45%)
After-hours: May 29, 2026, 7:57 PM EDT
Generate Biomedicines Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Generate Biomedicines stock has a consensus rating of "Strong Buy" and an average price target of $25.4. The average 1-year stock price forecast is 93.60% higher than the current stock price, while the lowest is $22 (+67.68%) and the highest is $30 (+128.66%).
Price Target: $25.4 (+93.60%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Generate Biomedicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|
| Strong Buy | 3 | 4 | 4 |
| Buy | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $22 | Buy | Maintains | $20 → $22 | +67.68% | May 14, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $24 | Buy | Reiterates | $24 | +82.93% | May 8, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +90.55% | May 8, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $26 | Buy | Maintains | $26 | +98.17% | Apr 10, 2026 |
| Guggenheim | Guggenheim | Buy Initiates $30 | Buy | Initiates | $30 | +128.66% | Mar 24, 2026 |
Financial Forecast
Revenue This Year
31.69M
from 31.89M
Decreased by -0.63%
Revenue Next Year
35.19M
from 31.69M
Increased by 11.03%
EPS This Year
-2.16
from -4.98
EPS Next Year
-2.15
from -2.16
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 39.1M | 42.0M | ||||||
| Avg | 31.7M | 35.2M | ||||||
| Low | 21.8M | 23.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 22.5% | 32.5% | ||||||
| Avg | -0.6% | 11.0% | ||||||
| Low | -31.7% | -26.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.74 | -1.82 | |
| Avg | -2.16 | -2.15 | |
| Low | -2.35 | -2.34 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.